Study ID	Treatment	Any AE	Serious AE	AE withdrawal	Other withdrawal
Bahra 2000	(1) Zolmitriptan 5 mg oral, n = 114 (2) Zolmitriptan 10 mg oral, n = 111 (3) Placebo, n = 115	Within 24 h: (1) 32/114 (2) 43/111 (3) 17/115 AE details reported for ITT population, not safety population	1 in (2), but 58 days after treatment, and not considered related	None in ITT population within 24 h of treatment One in safety population ‐ no details	20 pts did not have three episodes
Cittadini 2006	(1) Zolmitriptan 5 mg IN, n = 65 (2) Zolmitriptan 10 mg IN, n = 63 (3) Placebo, n = 61	No data	None	(1) 1/65 (shortness of breath, vomiting, rheumatic pain)	6 pts lost to follow‐up, 2 pts without clear reason after treating one episode
Ekbom 1991	(1) Sumatriptan 6 mg SC, n = 39 (2) Placebo, n = 39	No time specified: (1) 15/49 (2) 12/47	None reported	None	8 pts excluded due to protocol violations, 2 pts had only one episode
Ekbom 1993	(1) Sumatriptan 6 mg SC, n = 92 (2) Sumatriptan 12 mg SC, n = 88 (3) Placebo, n = 88	No time specified: (1) 34/101 (2) 42/94 (3) 15/96 (over 90% mild/mod)	None reported	(3) 1/101 (pressure on neck)	21 pts had only one episode
Rapoport 2007	(1) Zolmitriptan 5 mg IN, n = 52 (2) Zolmitriptan 10 mg IN, n = 49 (3) Placebo, n = 50	No time specified: (1) 13/52 (2) 16/49 (3) 8/50 (mild, non‐specific, typical of triptans)	None	None	12 pts lost to follow‐up, 5 withdrew consent, 9 did not have an episode
Van Vliet 2003	(1) Sumatriptan 20 mg IN, n = 77 (2) Placebo, n = 77	No data	None	No data	7 pts lost to follow‐up, 10 treated attacks of mild intensity
AE ‐ adverse event; IN ‐ intranasal; ITT ‐ intention‐to‐treat; n ‐ number of participants; pts ‐ participants; SC ‐ subcutaneous